之前剛好有醫生問,所以就整理表格如下:
Drug Treatment for Osteomyelitis
Agent |
Mechanism of Action |
Dosage |
Benefits |
Side Effects |
Notes |
Nafcillin sodium or oxacillin sodium |
Inhibition of cell-wall synthesis by attaching to penicillin-binding-protein targets |
1.5-2.0 g iv, every 4-6 h for 4-6 wk |
Active against methicillin-sensitiveS. aureus or coagulase-negative staphylococci |
Neutropenia, interstitial nephritis, hepatitis, rash |
Home use is difficult without a portable infusion pump due to frequent administration. Used more commonly in patients with bacteremia and infective endocarditis |
Cefazolin |
Inhibition of cell-wall synthesis by attaching to penicillin-binding-protein targets |
1-2 g iv, every 8 h for 4-6 wk |
Active against methicillin-sensitiveS. aureus or coagulase-negative staphylococci, and β-hemolytic streptococci |
Fever, rash, thrombophlebitis, diarrhea |
|
Vancomycin |
The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis |
15 mg/kg iv, every 12 h for 4-6 wk |
Active against MRSA or coagulase-negative staphylococci |
Ototoxicity, red man/neck syndrome, nausea, vomiting, neutropenia |
Monitor drug concentration regularly. Could be used as an alternative to cefazolin and nafcillin in patients with serious allergy to β-lactam |
Linezolid |
Linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process |
600 mg po or iv, every 12 h for 6 wk |
Active against vancomycin-resistant enterococci, vancomycin intermediate S. aureus |
Diarrhea, headache, nausea, myelosuppression |
High oral bioavailability. Could be used as an alternative to vancomycin or β-lactam in drug intolerance, resistance, or treatment failure. Patients receiving linezolid need to avoid consuming large amounts of foods or beverages with high tyramine content |
Levofloxacin |
Inhibition of bacterial topoisomerase IV and DNA gyrase, enzymes required for DNA replication, transcription, repair, and recombination |
500 mg/d po or iv |
Active against S. aureus and coagulase-negative staphylococci, and aerobic gram-negative bacilli |
Nausea, vomiting, diarrhea, headache, QT prolongation |
High oral bioavailability. Could be used in hardware-associatedosteomyelitis as an alternative to β-lactam or vancomycin in association with rifampin |
Rifampin |
Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible microorganisms |
600-900 mg, bid or tid |
Active against susceptible S. aureusand coagulase-negative staphylococci |
Nausea, vomiting, heartburn, thrombocytopenia, abnormal liver function tests, drug-drug interaction |
Rapid emergence of resistance when used as monotherapy. Should always be used in association with quinolones in hardware-associatedosteomyelitis as an alternative to β-lactam or vancomycin |
Aqueous crystalline penicillin G |
Inhibition of cell-wall synthesis by attaching to penicillin-binding-protein targets |
20 × 106U/24h iv, either continuously or in six equally divided doses for 4-6 wk |
Active against penicillin-susceptible streptococci, enterococci |
Rash or urticaria, hypersensitivity reactions, pseudomembranous colitis |
Could be used as a continuous infusion using a portable infusion pump in an ambulatory setting |
Ceftriaxone |
Inhibition of cell-wall synthesis by attaching to penicillin-binding-protein targets |
1-2 g iv or im, every 24 h for 4-6 wk |
Active against manyEnterobacteriaceae, β hemolytic streptococci |
Rash, injection site pain, diarrhea, reversible gallbladder disease |
Used once daily, convenient for outpatient therapy |
Cefepime |
Inhibition of cell-wall synthesis by attaching to penicillin-binding-protein targets |
1-2 g iv, every 12 h for 4-6 wk |
Active againstEnterobacteriaceae,P. aeruginosa orEnterobacter spp |
Diarrhea, dyspepsia, headache, pseudomembranous colitis, phlebitis, transient elevation in liver function tests |
|
Meropenem |
Inhibition of cell-wall synthesis by attaching to penicillin-binding-protein targets |
1g iv, every 8 h for 4-6 wk |
Active againstEnterobacteriaceae,P. aeruginosa orEnterobacter spp |
Diarrhea, nausea, vomiting |
Expensive, broad-spectrum |
* Recommendations are for adult, non-pregnant patients with normal renal function. |
bid = twice daily; DNA = deoxyribonucleic acid; im = intramuscular; iv = intravenous; MRSA = methicillin-resistantStaphylococcus aureus; po = oral; RNA = ribonucleic acid; tid = three times daily. |
資料來源:AHFS DI® Essentials
留言列表